Figure 2.

Expression of markers for activation, homing and degranulation.

Bone marrow-derived eosinophils were activated with IL-33 (IL-33 Eos) for 20 hrs or incubated with IL-5 (IL-5 Eos) as a control, and marker expression was evaluated using flow cytometry. (a) Histograms show representative flow cytometry experiments. Next to the histograms, the graphs show paired data of two treatments (IL-5 and IL-33). Data represent one of two independent experiments; n ≥ 5. (b) Expression of markers for homing and activation (Siglec-F and CD11b) and for degranulation (CD107a) were evaluated in tumor infiltrating eosinophils from IL-33- and vehicle-treated BALB/c mice (control) (s.c. tumor model; n = 7) and from (c) IL-33- and vehicle-treated (control) AOM+DSS mice (data pooled from two independent experiments; n = 12–18. Statistical differences were assessed by using paired and unpaired student’s t-test. *p < .05; **p < .01; ***p < .001.